Immunorizon
T-and NK-cell Engagers for Cancer Therapy
Health Tech & Life Sciences
Acquired by Purple Biotech on Feb, 2023
Company Overview
Snapshot
Founded in December 2017, Immunorizon operates with 1–10 employees. The company was acquired by Purple Biotech in February 2023, marking a significant milestone in its trajectory.
Business overview
Immunorizon is a Health Tech & Life Sciences company focused on developing advanced cancer therapies. The company specializes in creating conditionally activated tumor-restricted T- and NK-cell engagers, utilizing tri-specific constructs with additional tumor-associated antigens and diverse engagers for both T-cells and NK-cells. Operating within the Pharmaceuticals sector, Immunorizon's core technology targets oncology and immunology to address unmet needs in cancer treatment.
Log in to access full profile ›Company Intelligence Q&A
- What is Immunorizon's primary focus?
- Immunorizon is focused on developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy, utilizing tri-specific constructs with additional tumor-associated antigens.
- When was Immunorizon founded?
- Immunorizon was founded in December 2017.
- What is the status of Immunorizon?
- Immunorizon was acquired by Purple Biotech in February 2023.
- Which investors participated in Immunorizon's funding rounds?
- Immunorizon received funding from M Ventures and ExploreBio in its December 2017 seed round. M Ventures also participated in subsequent seed rounds in April 2019 and February 2020.
- What type of products does Immunorizon develop?
- Immunorizon develops biotechnology products, specifically antibodies for cancer therapy, which are currently in the clinical trial stage.